Ironwood Pharmaceuticals Inc(IRWD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 6:57 AM ET (Korea 9/11 19:57)
Full metrics table
| Index | RUT | P/E | 5.18 | EPS (ttm) | 0.77 | Insider Own | 3.73% | Shs Outstand | 165.2M | Perf Week | -9.98% |
| Market Cap | 0.66B | Forward P/E | 3.15 | EPS next Y | 2.86% | Insider Trans | -52.75% | Shs Float | 159.1M | Perf Month | -7.67% |
| Enterprise Value | 0.97B | PEG | 0.03 | EPS next Q | 0.33 | Inst Own | 98.05% | Short Float | 11.36% | Perf Quarter | 18.51% |
| Income | 0.13B | P/S | 1.69 | EPS this Y | 716.67% | Inst Trans | 0.15% | Short Ratio | 8.19 | Perf Half Y | 7.88% |
| Sales | 0.39B | P/B | - | EPS next 5Y | 112.04% | ROA | 41.35% | Short Interest | 18.07M | Perf YTD | 17.8% |
| Book/sh | -0.98 | P/C | 8.29 | EPS past 3/5Y | -46.07% -25.92% | ROE | - | 52W High | -31.31% ($5.78) | Perf Year | 245.22% |
| Cash/sh | 0.48 | P/FCF | 3.54 | Sales past 3/5Y | -10.32% -5.33% | ROIC | 56.04% | 52W Low | 278.1% ($1.05) | Perf 3Y | -51.88% |
| Dividend Est. | - | EV/EBITDA | 4.09 | EPS Y/Y TTM | 1922.25% | Gross Margin | 99.53% | Volatility(W/M) | 4.07% 4.88% | Perf 5Y | -67.46% |
| Dividend TTM | - | EV/Sales | 2.5 | Sales Y/Y TTM | 26.19% | Oper. Margin | 60.64% | ATR (14) | 0.2 | Perf 10Y | -64.87% |
| Dividend Ex-Date | - | Quick Ratio | 6.06 | EPS Q/Q | 123.29% | Profit Margin | 33.36% | RSI (14) | 42.96 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.06 | Sales Q/Q | 32.62% | SMA20 | -6.28% ($4.24) | Beta | 0.22 | Target Price | $6.1 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -4.73% ($4.17) | Rel Volume | 0.53 | Prev Close | $4.07 |
| Employees | 100 | LT Debt/Eq | - | EPS/Sales Surpr. | -3.13% -1.57% | SMA200 | 0.51% ($3.95) | Avg Volume(3M) | 2.21M | Price | $3.97 |
| IPO | 2010/2/3 | Option/Short | Yes/Yes | Trades | 5949 | Volume | 1,174,197 | Change | -2.46% |
Company
IRWD is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Ironwood Pharmaceuticals is a U.S. specialty pharmaceutical company focused on treatments for gastrointestinal (digestive) disorders. Its key asset is LINZESS (generic name: linaclotide), a treatment for irritable bowel syndrome and chronic idiopathic constipation, and it operates a pipeline targeting unmet needs in the digestive disease space.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
IRWD makes money exceptionally well
60.64% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +716.7% this year.
Tap to view numbers
The stock looks undervalued
Trading at 5.2 times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -51.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 98.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FDLS 0.01%
DEEP 0.01%
HULL 0.01%
BBC 0.01%
DSMC 0.01%It ranks #4 in the industry
Based on market cap of $656M.
IRWD $656M PER 5.2
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is IRWD?
IRWD belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of IRWD?
The market cap of IRWD is approximately $656M, ranking 2,995 within its sector.
What is the P/E ratio of IRWD?
IRWD has a P/E ratio of approximately 5.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for IRWD?
IRWD has recorded a 52-week high of $5.78 and a low of $1.05.
